Lazertinib
- Generic Name
- Lazertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N8O3
- CAS Number
- 1903008-80-9
- Unique Ingredient Identifier
- 4A2Y23XK11
- Background
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Lazertinib 160mg in EGFR T790M NSCLC
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 117
- Registration Number
- NCT05701384
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, MA, Korea, Republic of
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT05663866
- Locations
- 🇫🇷
Hopital Europeen Georges-Pompidou, Paris, France
🇫🇷CHU Rouen Hopital Charles Nicolle, Rouen, France
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05601973
- Locations
- 🇮🇹
SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
🇫🇷Chu Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 390
- Registration Number
- NCT05498428
- Locations
- 🇧🇷
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
🇧🇷Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil
🇧🇷Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Jin Hyoung Kang
- Target Recruit Count
- 28
- Registration Number
- NCT05477615
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hosptial, Seoul, Korea, Republic of
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 418
- Registration Number
- NCT05388669
- Locations
- 🇺🇸
City of Hope Duarte, Duarte, California, United States
🇵🇹Ulsm - Hosp. Pedro Hispano, Senhora da Hora, Portugal
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 900
- Registration Number
- NCT05377788
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Sung Yong Lee
- Target Recruit Count
- 77
- Registration Number
- NCT05338619
- Locations
- 🇰🇷
Kyungpook National University Medical Center, Daegu, Korea, Republic of
🇰🇷Koera University Guro Hospital, Seoul, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Target Recruit Count
- 49
- Registration Number
- NCT05299125
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Paraná, Brazil
🇧🇷Pronutrir - Oncologia e Nutrição, Fortaleza, Ceará, Brazil
🇧🇷Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 36
- Registration Number
- NCT05277701
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.